scleroderma
Information
- Disease name
- scleroderma
- Disease ID
- DOID:419
- Description
- "A rheumatic disease that involves the abnormal growth of connective tissue, which supports the skin and internal organs." [url:http\://www.niams.nih.gov/Health_Info/Scleroderma/default.asp, url:https\://scleroderma.org/]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04567537 | Active, not recruiting | N/A | Laser Treatment for the Improvement of Scars and Scleroderma | June 2, 2021 | May 2024 |
| NCT01895244 | Active, not recruiting | Phase 2 | Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis | September 2012 | September 2024 |
| NCT04491396 | Active, not recruiting | N/A | Yoga Adjunct for Scleroderma | January 8, 2020 | July 30, 2024 |
| NCT00074568 | Completed | Scleroderma Registry | September 2000 | January 2022 | |
| NCT00213525 | Completed | Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 Controls | October 2004 | October 2008 | |
| NCT00319033 | Completed | Phase 2/Phase 3 | Open-label Study With Bosentan in Interstitial Lung Disease | July 2004 | February 2006 |
| NCT00372398 | Completed | Premature Coronary Atherosclerosis in Scleroderma | October 2006 | July 2010 | |
| NCT00377949 | Completed | Multi-center, Web Based Observational Study of Pulmonary Hypertension in Scleroderma Patients | February 2005 | ||
| NCT00419419 | Completed | Phase 3 | Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon | December 2006 | |
| NCT00005675 | Completed | Phase 2 | Oral Type I Collagen for Relieving Scleroderma | April 2000 | |
| NCT00007267 | Completed | Phase 2 | Psychological Treatments for Scleroderma | June 2001 | June 2006 |
| NCT00043706 | Completed | Phase 1/Phase 2 | Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis | September 2003 | |
| NCT00476801 | Completed | N/A | UVA1 Light for Treatment of Scleroderma and Similar Conditions | July 2001 | February 2004 |
| NCT00498615 | Completed | Phase 3 | A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon | April 2007 | March 2012 |
| NCT00501995 | Completed | Phase 3 | High Dose Cyclophosphamide for Treatment of Scleroderma | February 2001 | May 2010 |
| NCT00513591 | Completed | Duke Autoimmunity in Pregnancy Registry | August 2007 | November 19, 2018 | |
| NCT00540566 | Completed | Optical Biopsy of Human Skin in Conjunction With Laser Treatment | June 1999 | July 2008 | |
| NCT00566137 | Completed | Sleep Disturbances and Pulmonary Artery/Aorta Diameter in Scleroderma Patient | February 2006 | February 2007 | |
| NCT00740285 | Completed | Phase 2/Phase 3 | Effectiveness and Safety of Lidocaine for Scleroderma | April 2004 | April 2007 |
| NCT00764309 | Completed | Phase 1/Phase 2 | Safety Evaluation of Dasatinib in Subjects With Scleroderma Pulmonary Fibrosis | January 2009 | April 2011 |
| NCT00775463 | Completed | Phase 2 | Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine | May 2009 | July 2011 |
| NCT00883129 | Completed | Phase 2 | Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II) | September 2009 | November 2015 |
| NCT00930683 | Completed | Phase 1 | A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma | September 2009 | July 2011 |
| NCT00946699 | Completed | Phase 1 | A Study of the Safety and Tolerability of MEDI-551 in Scleroderma | March 2010 | March 2014 |
| NCT01093885 | Completed | N/A | Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis | February 2010 | July 2016 |
| NCT01111786 | Completed | Finger Hardness Measure in Scleroderma | April 2010 | January 2013 | |
| NCT01117298 | Completed | Phase 3 | A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma | November 2009 | May 2010 |
| NCT01538719 | Completed | Phase 1/Phase 2 | IL1-TRAP, Rilonacept, in Systemic Sclerosis | December 2011 | August 11, 2017 |
| NCT01570764 | Completed | Phase 3 | Cyclophosphamide Systemic Sclerosis Associated Interstitial Lung Disease | January 14, 2013 | February 22, 2018 |
| NCT01762449 | Completed | Morbidity and Mortality Follow Up for the Scleroderma Lung Study | July 2012 | August 2013 | |
| NCT01862926 | Completed | Phase 2/Phase 3 | Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD | November 2014 | January 2021 |
| NCT01878526 | Completed | Phase 3 | Gastroesophageal Reflux Treatment in Scleroderma | June 2013 | January 2016 |
| NCT01931644 | Completed | At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions | July 2013 | April 2024 | |
| NCT01959815 | Completed | Novel Screening Strategies for Scleroderma PAH | September 26, 2013 | November 6, 2019 | |
| NCT02006420 | Completed | Scleroderma ARFI Imaging of the Skin | December 2013 | December 2015 | |
| NCT02047708 | Completed | Phase 2 | Zibotentan Better Renal Scleroderma Outcome Study | October 2014 | October 2017 |
| NCT02062125 | Completed | Calcinosis in a Single-Center Scleroderma Population | October 31, 2012 | March 15, 2024 | |
| NCT02165111 | Completed | Phase 3 | Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome | January 2015 | September 2015 |
| NCT02240888 | Completed | N/A | Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response | October 2011 | May 31, 2018 |
| NCT02331225 | Completed | Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension | December 2014 | October 2016 | |
| NCT02370693 | Completed | Phase 2 | Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis | March 2016 | January 1, 2020 |
| NCT02370784 | Completed | Phase 2 | Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma | February 2015 | December 15, 2019 |
| NCT02396238 | Completed | N/A | Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR) | May 15, 2015 | May 22, 2018 |
| NCT02426229 | Completed | Phase 1 | Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma | February 2016 | June 21, 2018 |
| NCT02494401 | Completed | N/A | Taking Charge of Systemic Sclerosis | March 6, 2016 | February 2018 |
| NCT02610842 | Completed | N/A | Hands on - a Hand Care Guide in Systemic Sclerosis | January 2015 | October 2015 |
| NCT02733978 | Completed | N/A | Ozone Therapy in the Treatment of Digital Ulcers in Patients With Systemic Sclerosis | June 2016 | October 2016 |
| NCT02798055 | Completed | Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis | September 30, 2016 | June 30, 2019 | |
| NCT02835196 | Completed | Optical Elastography of Systemic Sclerosis Skin | October 25, 2017 | November 1, 2018 | |
| NCT02837549 | Completed | N/A | Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma | July 2016 | September 2017 |
| NCT02887495 | Completed | The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma) | July 2014 | February 2, 2022 | |
| NCT02896205 | Completed | Phase 3 | Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease | October 2016 | July 1, 2017 |
| NCT02915835 | Completed | Phase 2 | Riociguat in Scleroderma Associated Digital Ulcers | September 2016 | July 24, 2018 |
| NCT03092024 | Completed | N/A | Scleroderma Patient-centered Intervention Network (SPIN) Hand Program Feasibility Study | June 1, 2017 | October 17, 2017 |
| NCT03141125 | Completed | N/A | The Effect of Ethanol Extract Physalis Angulata Linn. in Scleroderma Patients With Standard Therapy | January 2016 | August 2017 |
| NCT03207997 | Completed | N/A | MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients | September 18, 2017 | March 9, 2018 |
| NCT03222492 | Completed | Phase 1/Phase 2 | Brentuximab Vedotin for Systemic Sclerosis | September 20, 2017 | April 10, 2023 |
| NCT03274076 | Completed | Phase 1/Phase 2 | Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) | September 25, 2017 | November 15, 2019 |
| NCT03294616 | Completed | N/A | Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma | February 6, 2017 | November 20, 2019 |
| NCT03419208 | Completed | N/A | Scleroderma Patient-centered Intervention Network (SPIN) Hand Program | March 12, 2018 | May 30, 2020 |
| NCT03508661 | Completed | N/A | The Scleroderma Patient-centered Intervention Network (SPIN) Support Group Leader Education Program Feasibility Trial | April 18, 2018 | August 10, 2018 |
| NCT03742466 | Completed | N/A | Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients | November 10, 2018 | September 30, 2019 |
| NCT03914781 | Completed | N/A | SPIN Self-Management Feasibility Trial | July 5, 2019 | November 25, 2019 |
| NCT04179292 | Completed | N/A | The Effect of Physiotherapy Program in Scleroderma Patients | November 21, 2019 | January 27, 2021 |
| NCT04273386 | Completed | N/A | Mouth Handicap in Systemic Sclerosis | December 2, 2019 | March 20, 2022 |
| NCT04335279 | Completed | N/A | Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program | April 9, 2020 | July 24, 2020 |
| NCT04481984 | Completed | N/A | Effectiveness of a Home-based, Self-administered Exercise Program for Hands in Patients With Systemic Sclerosis | July 15, 2016 | June 5, 2019 |
| NCT04523506 | Completed | Early Phase 1 | The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma | May 8, 2020 | April 22, 2021 |
| NCT04588714 | Completed | N/A | Feasibility and Preliminary Effects of the Resilience-based, Energy Management to Enhance Wellbeing in Systemic Sclerosis (RENEW) Intervention | October 27, 2020 | May 31, 2021 |
| NCT04684225 | Completed | N/A | Telerehabilitation on Hand-Affected Scleroderma | January 6, 2021 | November 1, 2021 |
| NCT04908943 | Completed | N/A | RENEW Scleroderma: A Peer-Mentored, Web Intervention for Resilience-based, Energy Management to Enhance Wellbeing and Fatigue | August 28, 2021 | May 29, 2023 |
| NCT05080738 | Completed | N/A | Upper Extremity Home Exercises in Patients With Scleroderma | September 10, 2021 | June 15, 2022 |
| NCT05617066 | Completed | N/A | Stress, Scleroderma and Quality of Life | November 26, 2022 | September 1, 2023 |
| NCT05963048 | Completed | Phase 2/Phase 3 | Rituxmab Versus IL-6 in Treating ILD | December 1, 2021 | June 1, 2023 |
| NCT06095921 | Completed | N/A | The Effect of a Self-Management Program on Individuals With Scleroderma | July 15, 2020 | January 15, 2021 |
| NCT04875078 | Enrolling by invitation | N/A | UVA-1 for Treatment of Skin Tightening and Improvement of Hand Function in Scleroderma | December 12, 2020 | December 2024 |
| NCT01374282 | No longer available | Post Marketing Surveillance Study of Cuprimine | |||
| NCT03800017 | Not yet recruiting | N/A | Skeletal Muscle Function in Interstitial Lung Disease | June 1, 2024 | December 31, 2026 |
| NCT05870852 | Not yet recruiting | N/A | Effectiveness of ESWT and PNF in Scleroderma With Calcinosis | May 22, 2023 | May 22, 2024 |
| NCT04966416 | Not yet recruiting | N/A | Calcinosis Reduction by Pyrophosphate in SSC | August 1, 2023 | June 30, 2026 |
| NCT06264492 | Not yet recruiting | Delving Into Participation Trends of Scleroderma Clinical Trials | March 2025 | March 2027 | |
| NCT06373263 | Not yet recruiting | N/A | Evaluating Tools to Communicate Scleroderma Research Results to Patients | June 2024 | June 2024 |
| NCT05785403 | Not yet recruiting | Co-designing Digital Ulcers Opportunities With Patients and Clinicians | June 2023 | June 2024 | |
| NCT02450396 | Recruiting | Pregnancy and Medically Assisted Conception in Rare Diseases | June 2014 | December 2025 | |
| NCT06195072 | Recruiting | Phase 2 | Platform Clinical Study for Conquering Scleroderma | April 1, 2024 | November 2026 |
| NCT04746313 | Recruiting | Prevalence of Hyperprolactinemia in Systemic Scleroderma | March 1, 2021 | March 2023 | |
| NCT04797286 | Recruiting | Phase 2 | Sildenafil for Early Pulmonary Vascular Disease in Scleroderma | September 20, 2021 | September 2024 |
| NCT05251415 | Recruiting | Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases | April 4, 2022 | April 4, 2032 | |
| NCT04265144 | Recruiting | N/A | Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre | June 8, 2020 | June 2030 |
| NCT04402086 | Recruiting | Rheumatology Patient Registry and Biorepository | August 4, 2020 | June 1, 2030 | |
| NCT04464434 | Recruiting | Phase 4 | Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis | September 17, 2020 | October 1, 2030 |
| NCT05925803 | Recruiting | Phase 3 | Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | November 8, 2023 | December 31, 2027 |
| NCT06339957 | Recruiting | Rheumatology Diet Study | March 1, 2024 | July 1, 2024 | |
| NCT05085444 | Recruiting | Early Phase 1 | A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma | October 8, 2021 | October 8, 2024 |
| NCT04535245 | Recruiting | Lung Clearance Index to Identify Scleroderma Patients at Risk for ILD | January 4, 2021 | January 15, 2026 | |
| NCT03276923 | Recruiting | Maternal Autoimmune Disease Research Alliance (MADRA) Registry | January 1, 2018 | January 1, 2027 | |
| NCT05236491 | Recruiting | Phase 2/Phase 3 | COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases | March 9, 2022 | December 2023 |
| NCT05995626 | Recruiting | Early Phase 1 | Hyaluronidase Via LADD Scleroderma-induced Microstomia | March 1, 2024 | January 2025 |
| NCT04610788 | Recruiting | Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH | April 15, 2019 | December 31, 2024 | |
| NCT05204355 | Recruiting | MRI for Screening and Monitoring Scleroderma ILD | May 1, 2022 | October 31, 2025 | |
| NCT05041868 | Recruiting | N/A | Rehabilitation Program in Patients With Scleroderma | October 15, 2021 | December 31, 2025 |
| NCT03840928 | Recruiting | PatientSpot Formerly Known as ArthritisPower | April 1, 2015 | March 1, 2025 | |
| NCT06328777 | Recruiting | Phase 1/Phase 2 | RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis | June 2024 | July 2029 |
| NCT05168215 | Recruiting | Effectiveness of Bosentan Therapy in Patients With Systemic scleRosis and Progressive Digital ulcEr Disease. | January 1, 2022 | June 1, 2024 | |
| NCT05635266 | Recruiting | Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives | October 26, 2021 | October 2025 | |
| NCT05098704 | Recruiting | Phase 2/Phase 3 | Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk | June 22, 2022 | June 2030 |
| NCT01656447 | Recruiting | Scleroderma Registry & Repository at the Hospital for Special Surgery | August 2006 | January 2030 | |
| NCT04246528 | Recruiting | N/A | SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF) | September 15, 2021 | May 2026 |
| NCT01793168 | Recruiting | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford | July 2010 | December 2100 | |
| NCT03740724 | Terminated | Phase 1/Phase 2 | A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea) | December 18, 2019 | April 21, 2022 |
| NCT00204763 | Terminated | Phase 4 | Comparison of Esophageal and Anorectal Manometry Catheters | January 2004 | April 2007 |
| NCT04837131 | Terminated | Phase 2 | A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients | April 28, 2021 | February 23, 2024 |
| NCT03937856 | Terminated | N/A | Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases | May 7, 2019 | April 22, 2021 |
| NCT03411057 | Terminated | Mindfulness Based Stress Reduction in Rheumatic Diseases | January 18, 2018 | April 22, 2021 | |
| NCT00040651 | Terminated | Phase 1 | Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients | July 2002 | March 2007 |
| NCT04178616 | Terminated | N/A | Assessment of the Prevalence of Olfactory Disorders in Systemic Scleroderma | December 31, 2019 | March 13, 2020 |
| NCT01545427 | Terminated | Phase 2 | Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma | April 2008 | December 2008 |
| NCT00476697 | Terminated | N/A | UVA1 Light for Scleroderma and Similar Conditions | January 1997 | July 2003 |
| NCT03593902 | Terminated | Phase 2/Phase 3 | Cardiac Safe Transplants for Systemic Sclerosis | May 17, 2018 | October 9, 2019 |
| NCT00282425 | Terminated | Phase 1 | Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis | May 2005 | December 2012 |
| NCT05181644 | Terminated | N/A | Effectiveness of the EmoLED Medical Device in the Healing of Digital Ulcers in Patients With Scleroderma. | April 22, 2022 | March 6, 2024 |
| NCT02851875 | Terminated | Duke Scleroderma Clinic Patient Registry | April 2016 | May 7, 2018 | |
| NCT01642706 | Unknown status | Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments | July 2, 2012 | December 2020 | |
| NCT05204784 | Unknown status | N/A | Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis | February 28, 2022 | June 2024 |
| NCT03459716 | Unknown status | Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension | June 1, 2018 | December 1, 2021 | |
| NCT03560154 | Unknown status | N/A | Effects of Whole Body Vibration Training in Patients With Interstitial Lung Disease | January 2017 | September 2020 |
| NCT03726398 | Unknown status | Phase 2/Phase 3 | CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH | September 1, 2018 | December 1, 2020 |
| NCT01553890 | Unknown status | N/A | Empirical Comparative Study of Variation Blood Level Antibody Vitamin D at Scleroderma (SSc) Patients Compared Healthy Peoples | March 2012 | March 2013 |
| NCT02302352 | Unknown status | Phase 3 | Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosis | December 2014 | January 2016 |
| NCT04563481 | Unknown status | N/A | Effectiveness of Telerehabilitation on Scleroderma | May 1, 2022 | December 30, 2023 |
| NCT04630782 | Unknown status | Evaluating Gut Imaging and Stool Biomarkers in Patients With Scleroderma-associated Gastrointestinal Disease | April 9, 2020 | January 31, 2023 | |
| NCT02680717 | Withdrawn | Phase 1 | Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea | March 2016 | May 2017 |
| NCT02588625 | Withdrawn | Phase 2 | A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc) | February 2016 | October 2019 |
| NCT04656704 | Withdrawn | Early Phase 1 | Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease | January 1, 2020 | January 1, 2022 |
| NCT02328625 | Withdrawn | Scleroderma Treatment With Celution Processed ADRCs Registry | April 2015 | June 2017 | |
| NCT02166229 | Withdrawn | Phase 1/Phase 2 | Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma | June 2014 | August 2014 |
| NCT01639573 | Withdrawn | Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis | April 2011 | September 2, 2018 | |
| NCT01497743 | Withdrawn | Phase 4 | Probiotics in Patients With Moderate-to-severe Distention/ Bloating From Systemic Sclerosis | February 2012 | |
| NCT03270722 | Withdrawn | N/A | Functional Luminal Imaging Probe (FLIP) Topography Use in Patients With Scleroderma and Trouble Swallowing | January 1, 2018 | May 2020 |
- Disase is a (Disease Ontology)
- DOID:1575
- Cross Reference ID (Disease Ontology)
- MESH:D012594
- Cross Reference ID (Disease Ontology)
- NCI:C26746
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:201440007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0011644
- Exact Synonym (Disease Ontology)
- dermatosclerosis
- HPO alt_id (Human Phenotype Ontology)
- HP:0001594
- HPO alt_id (Human Phenotype Ontology)
- HP:0007426
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0100324
- OrphaNumber from OrphaNet (Orphanet)
- 801